Tyrosine Kinases / Adaptors

プロトコール

抗体比較

ポジティブコントロール

下記ステップについては、データシートの右側もあわせてご参照ください。

IHC-P: 抗体希釈液 / 抗原賦活化

Fibroblast growth factors (FGFs) produce mitogenic and angiogenic effects in target cells by signaling through cell surface receptor tyrosine kinases. There are four members of the FGF receptor family: FGFR-1 (flg), FGFR-2 (bek, KGFR), FGFR-3, and FGFR-4. Each receptor contains an extracellular ligand binding domain, a transmembrane domain, and a cytoplasmic kinase domain (1). Following ligand binding and dimerization, the receptors are phosphorylated at specific tyrosine residues (2). Seven tyrosine residues in the cytoplasmic tail of FGFR-1 can be phosphorylated: Tyr463, 583, 585, 653, 654, 730, and 766. Tyr653 and Tyr654 are important for catalytic activity of activated FGFR and are essential for signaling (3). The other phosphorylated tyrosine residues may provide docking sites for downstream signaling components such as Crk and PLCγ (4,5).

Activating mutations within fibroblast growth factor receptor 3 (FGFR-3) are responsible for human skeletal dysplasias including achondroplasia and the neonatal lethal syndromes thanatophoric dysplasia types I and II (6). Several of these same FGFR-3 mutations as well as overexpression of FGFR-3 proteins have also been identified somatically in human cancers, including multiple myeloma, bladder carcinoma and cervical cancer (7). Thus, FGFR-3 may represent a potential target for therapy.

1. Powers, C.J. et al. (2000) Endocr Relat Cancer 7, 165-97.
2. Reilly, J.F. et al. (2000) J Biol Chem 275, 7771-8.
3. Mohammadi, M. et al. (1996) Mol Cell Biol 16, 977-89.
4. Mohammadi, M. et al. (1991) Mol Cell Biol 11, 5068-78.
5. Larsson, H. et al. (1999) J Biol Chem 274, 25726-34.
6. Wilkie, A.O. et al. (2002) Am J Med Genet 112, 266-78.
7. Miyake, M. et al. (2007) Biochem Biophys Res Commun 362, 865-71.

本製品は試験研究用です。

FGF Receptor 3 (C51F2) Rabbit mAb

©1999-2012 Cell Signaling Technology, Inc.

問合せ

FGF Receptor 3 (C51F2) Rabbit mAbのCSTジャパン